CSO @Intelliatx 🇺🇸🇦🇷 #GeneEditing #CRISPR #WomenInSTEM Opinions/likes/RT mine & not endorsements.
Boston, MA
Joined April 2014
- Tweets358
- Following349
- Followers968
- Likes1.7K
Laura Sepp-Lorenzino retweeted
Thank you to all our members who voted in the recent election!
We are pleased to announce the new OTS BOD for the 2026-2027 term.
2026-2027 OTS Board of Directors
Learn more about our new BOD at
oligotherapeutics.org/the-so…
#ots #oligotherapeutics #oligonucleotidetherapeutics
Laura Sepp-Lorenzino retweeted
#HAE $NTLA News: Intellia presents positive results from the Phase 2 study of NTLA-2002 for #hereditaryangioedema at the @ACAAI Scientific Meeting in Boston. Details here: ir.intelliatx.com/news-relea…
Laura Sepp-Lorenzino retweeted
$NTLA News: This morning, Intellia announced a strategic collaboration with @ReCodeTx to develop novel #geneeditingtherapies for #cysticfibrosis. Full details here: ir.intelliatx.com/news-relea…
#CRISPR #CF
Laura Sepp-Lorenzino retweeted
Huge congratulations to @VertexPharma and @CRISPRTX for making history with the first-ever FDA approval of a #CRISPR therapy!
Laura Sepp-Lorenzino retweeted
Save the Date: In November, Intellia will present updated data from the ongoing Phase 1 study of NTLA-2001 for the potential treatment of #ATTR and hold an investor call to share third quarter 2023 earnings. Full details here: bit.ly/3QynQDI
#CRISPR #GeneEditing
Laura Sepp-Lorenzino retweeted
$NTLA News: Today, Intellia and @Regeneron announced an expanded research collaboration to explore additional CRISPR-based therapies for the treatment of neurological and muscular diseases. Full details here: bit.ly/3PYOIMM
#CRISPR #geneediting
Laura Sepp-Lorenzino retweeted
Congratulations to our friends at @SparingVision for selecting a second target as part of our ongoing collaboration to develop #CRISPR-based #geneediting technologies for the treatment of ocular diseases. We look forward to our continued partnership!
🤝 We are delighted to announce that we have selected a second target as part of our strategic collaboration with @intelliatx! 🚀 Read the full announcement here: sparingvision.com/sparingvis… #Ophthalmology #GenomicMedicines #GeneTherapy #Collaboration
Laura Sepp-Lorenzino retweeted
Don’t miss the opportunity to join us for NanoDDS on Sept 15-17th at MIT.
In person and virtual options are available.
Trainees - you can present posters, and a subset will be selected for oral presentation.
This quoted post is unavailable.
Laura Sepp-Lorenzino retweeted
$NTLA News: Today, we announced that updated interim data from the ongoing Phase 1/2 study of investigational NTLA-2002 for the treatment of #HAE will be presented at the upcoming @EAACI_HQ Congress. The presentation will be followed by a June 12th investor webcast: ow.ly/2RTP50OAAqy
#EAACI2023 #CRISPR #GenomeEditing
Laura Sepp-Lorenzino retweeted
In 2021, we collaborated with @SparingVision to develop novel genomic medicines utilizing #CRISPR for the potential treatment of ocular diseases. Today, we're proud to join together in recognition of #HealthyVisionMonth: ow.ly/9VHn50OupkP.👁️
#GeneEditing #RetinalDiseases
Laura Sepp-Lorenzino retweeted
Stories: Sonia Valliabh, @LauraSepplore, Tracy Cole, @timyub. Advancing care for rare. I learned so much from these brilliant scientists. Then 1on1 with Illumina’s Amanda Cashin. Collaborate to Investigate. Participate to Advocate. Communicate to Educate. Activate to Legislate!!
Laura Sepp-Lorenzino retweeted
$NTLA will host a virtual investor event to present interim data from the first-in-human clinical studies of NTLA-2002 and NTLA-2001 on Sept. 16, 2022, at 8 a.m. ET. Full details here: bit.ly/3cZzypL
Laura Sepp-Lorenzino retweeted
We are excited to announce the second annual webinar in the series "Med platforms Matter"! Confirmed speakers are Giovanni Traverso, @LauraSepplore and @raflynn5.
Editors from @Matter_CP and @MedCellPress will moderate the webinar. Sign up here: hubs.li/Q01cG2d10
Laura Sepp-Lorenzino retweeted
This #Juneteenth, we reflect on what we have done to create a future with equal opportunities and what we will continue to do. Join us this #FreedomDay by learning something new about the day and how you can support the community.
Laura Sepp-Lorenzino retweeted
Join us on May 17th for a conversation with John Leonard, CEO of Intellia Therapeutics.
This event is free for all Harvard alumni and HCC members.
Register here: harvardclubchicago.org/upcom…
Laura Sepp-Lorenzino retweeted
We’re honored to be recognized on this year’s @BostonGlobe 2021 #TopPlacestoWork list! Our incredible team makes all the difference! Congratulations to all who made the list: bostonglobe.com/2021/12/01/m… #OneIntellia
Laura Sepp-Lorenzino retweeted
Thank you, @ScienceMagazine, for highlighting Intellia’s investigational in vivo #CRISPR candidate, NTLA-2001, as one of the breakthroughs of the year for 2021! We are humbled to share this moment with the many other prestigious companies on this list. #genomeediting
AI algorithms can now churn out predictions for the 3D shapes of proteins with a precision matching that of painstaking laboratory techniques. The programs, and the blizzard of protein structures they have revealed, are Science’s 2021 #BOTY. fcld.ly/twr28jc
Laura Sepp-Lorenzino retweeted
$NTLA News: Intellia receives authorization for its Clinical Trial Application by the New Zealand Medicines and Medical Devices Safety Authority to initiate a Phase 1/2 clinical trial of NTLA-2002 for the treatment of #HAE. Full press release here: ir.intelliatx.com/news-relea… #CRISPR
Laura Sepp-Lorenzino retweeted
(L to R, top to bottom): @BuijsenRonald @StevenDowdy9 Martin Maier, Mike Gait, @RigoRnaIt @jwattsgroup @Bluebird__47 @oligogirl @LauraSepplore Marc Lemaitre, Richard Geary @DANorDNA Shalini Andersson, Fritz Eckstein, David Corey, @isa_aznarez @Giangran1Paloma